Vaccines against COVID-19: Priority to mRNA-Based Formulations

Pascolo, 2004, Messenger RNA-based vaccines, Expert Opin. Biol. Ther., 4, 1285, 10.1517/14712598.4.8.1285

Pascolo, 2006, Vaccination with messenger RNA, DNA Vaccines, 127, 23, 10.1385/1-59745-168-1:23

Bauer, 2008, Vaccination with messenger RNA (mRNA), Toll-Like Receptors (TLRs) and Innate Immunity. Handbook of Experimental Pharmacology, Volume 183, 221, 10.1007/978-3-540-72167-3_11

Pascolo, 2015, The messenger’s great message for vaccination, Expert Rev. Vaccines, 14, 153, 10.1586/14760584.2015.1000871

Pascolo, 2017, Messenger RNA: The inexpensive biopharmaceutical, J. Multidiscip. Eng. Sci. Technol., 4, 6937

Martinon, 1993, Induction of virus-specific cytotoxic T lymphocytesin vivo by liposome-entrapped mRNA, Eur. J. Immunol., 23, 1719, 10.1002/eji.1830230749

Conry, 1995, Characterization of a messenger RNA polynucleotide vaccine vector, Cancer Res., 55, 1397

Hoerr, 2000, In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies, Eur. J. Immunol., 30, 1, 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#

Polack, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N. Engl. J. Med., 383, 2603, 10.1056/NEJMoa2034577

Pallesen, 2017, Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen, Proc. Natl. Acad. Sci. USA, 114, E7348, 10.1073/pnas.1707304114

Wu, S., Huang, J., Zhang, Z., Wu, J., Zhang, J., Hu, H., Zhu, T., Zhang, J., Luo, L., and Fan, P. (2021). Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis., 10, Online ahead of print.

Zabaleta, 2021, An AAV-based, room-temperature stable, single dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates, Cell Host Microbe, 29, 1437, 10.1016/j.chom.2021.08.002

Trimpert, 2021, Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding, Cell Rep., 36, 109493, 10.1016/j.celrep.2021.109493

Wang, 2021, Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy, Proc. Natl. Acad. Sci. USA, 118, e2102775118, 10.1073/pnas.2102775118

Tscherne, 2021, Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination, bioRxiv, 118, e2026207118

Dertzbaugh, 1998, Genetically engineered vaccines: An overview, Plasmid, 39, 100, 10.1006/plas.1997.1329

Keech, 2020, Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine, N. Engl. J. Med., 383, 2320, 10.1056/NEJMoa2026920

Heath, 2021, Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine, N. Engl. J. Med., 385, 1172, 10.1056/NEJMoa2107659

Chawla, 2008, Adenovirus-vectored vaccines, Expert Opin. Ther. Patents, 18, 293, 10.1517/13543776.18.3.293

Stephen, 2010, Chromosomal integration of adenoviral vector DNA in vivo, J. Virol., 84, 9987, 10.1128/JVI.00751-10

Knoll, 2021, Oxford–AstraZeneca COVID-19 vaccine efficacy, Lancet, 397, 72, 10.1016/S0140-6736(20)32623-4

Voysey, 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3

Greinacher, 2021, Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, N. Engl. J. Med., 384, 2092, 10.1056/NEJMoa2104840

Logunov, 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia, Lancet, 397, 671, 10.1016/S0140-6736(21)00234-8

Sadoff, 2021, Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine, N. Engl. J. Med., 384, 1824, 10.1056/NEJMoa2034201

Pascolo, 2005, HLA class I transgenic mice: Development, utilisation and improvement, Expert Opin. Biol. Ther., 5, 919, 10.1517/14712598.5.7.919

Pascolo, 1997, HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice, J. Exp. Med., 185, 2043, 10.1084/jem.185.12.2043

Probst, 2006, Characterization of the ribonuclease activity on the skin surface, Genet. Vaccines Ther., 4, 4, 10.1186/1479-0556-4-4

Probst, 2007, Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent, Gene Ther., 14, 1175, 10.1038/sj.gt.3302964

Carralot, 2004, Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines, Cell. Mol. Life Sci., 61, 2418, 10.1007/s00018-004-4255-0

Scheel, 2004, Immunostimulating capacities of stabilized RNA molecules, Eur. J. Immunol., 34, 537, 10.1002/eji.200324198

Scheel, 2005, Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA, Eur. J. Immunol., 35, 1557, 10.1002/eji.200425656

Rittig, 2011, Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients, Mol. Ther., 19, 990, 10.1038/mt.2010.289

Weide, 2008, Results of the first phase I/II clinical vaccination trial with direct injection of mRNA, J. Immunother., 31, 180, 10.1097/CJI.0b013e31815ce501

Weide, 2009, Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients, J. Immunother., 32, 498, 10.1097/CJI.0b013e3181a00068

Verbeke, 2021, The dawn of mRNA vaccines: The COVID-19 case, J. Control. Release, 333, 511, 10.1016/j.jconrel.2021.03.043

Verbeke, 2019, Three decades of messenger RNA vaccine development, Nano Today, 28, 100766, 10.1016/j.nantod.2019.100766

Henderson, 2021, Cap 1 messenger RNA Synthesis with Co-transcriptional CleanCap® analog by in vitro transcription, Curr. Protoc., 1, e39, 10.1002/cpz1.39

Melton, 1984, Efficientin vitrosynthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter, Nucleic Acids Res., 12, 7035, 10.1093/nar/12.18.7035

Scheel, 2006, Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA, Eur. J. Immunol., 36, 2807, 10.1002/eji.200635910

Pardi, 2018, mRNA vaccines—A new era in vaccinology, Nat. Rev. Drug Discov., 17, 261, 10.1038/nrd.2017.243

Kranz, 2016, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature, 534, 396, 10.1038/nature18300

Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 222, 10.1038/nature23003

Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4

Sahin, 2020, COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses, Nature, 586, 594, 10.1038/s41586-020-2814-7

Walsh, 2020, Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates, N. Engl. J. Med., 383, 2439, 10.1056/NEJMoa2027906

van Doremalen, N., Fischer, R.J., Schulz, J.E., Holbrook, M.G., Smith, B.J., Lovaglio, J., Petsch, B., and Munster, V.J. (2021). Immunogenicity of low-dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. Viruses, 13.

Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N. Engl. J. Med., 384, 403, 10.1056/NEJMoa2035389

Buckstein, 2005, Suppression of RNA Recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA, Immunity, 23, 165, 10.1016/j.immuni.2005.06.008

Pardi, 2017, Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge, Nat. Commun., 8, 14630, 10.1038/ncomms14630

Honke, 2011, Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus, Nat. Immunol., 13, 51, 10.1038/ni.2169

Wang, 2021, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nat. Cell Biol., 592, 616

Dagan, 2021, BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting, N. Engl. J. Med., 384, 1412, 10.1056/NEJMoa2101765

Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A.P., Maruste, R., and Kärner, J. (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health-Eur., 100208. in press.

Haas, E.J., McLaughlin, J.M., Khan, F., Angulo, F.J., Anis, E., Lipsitch, M., Singer, S.R., Mircus, G., Brooks, N., and Smaja, M. (2021). Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: A retrospective surveillance study. Lancet Infect. Dis., 10, online ahead of print.